Nuveen
TEVA icon

Nuveen’s Teva Pharmaceuticals TEVA Stock Holding History

Nuveen’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$109M Buy
3,230,980
+489,957
+18% +$16.3M 0.03% 402
2026
Q1 		$82.6M Buy
2,741,023
+18,239
+0.7% +$587K 0.02% 454
2025
Q4 		$85M Buy
2,722,784
+708,400
+35% +$17.5M 0.02% 448
2025
Q3 		$40.7M Sell
2,014,384
-163,899
-8% -$2.88M 0.01% 724
2025
Q2 		$36.5M Sell
2,178,283
-477,994
-18% -$7.71M 0.01% 752
2025
Q1 		$40.8M Sell
2,656,277
-200,730
-7% -$3.59M 0.01% 718
2024
Q4 		$63M Buy
2,857,007
+182,774
+7% +$3.33M 0.02% 555
2024
Q3 		$48.2M Buy
2,674,233
+77,400
+3% +$1.35M 0.01% 683
2024
Q2 		$42.2M Sell
2,596,833
-39,233
-1% -$604K 0.01% 708
2024
Q1 		$37.2M Buy
2,636,066
+975,556
+59% +$12.3M 0.01% 781
2023
Q4 		$17.3M Buy
1,660,510
+54,100
+3% +$505K 0.01% 1244
2023
Q3 		$16.4M Buy
1,606,410
+106,000
+7% +$987K 0.01% 1158
2023
Q2 		$11.3M Buy
1,500,410
+23,700
+2% +$192K ﹤0.01% 1431
2023
Q1 		$13.1M Buy
1,476,710
+121,600
+9% +$1.2M ﹤0.01% 1311
2022
Q4 		$12.4M Sell
1,355,110
-226,154
-14% -$1.97M ﹤0.01% 1354
2022
Q3 		$12.8M Buy
1,581,264
+133,579
+9% +$1.18M 0.01% 1326
2022
Q2 		$10.9M Sell
1,447,685
-35,743
-2% -$311K ﹤0.01% 1445
2022
Q1 		$13.9M Sell
1,483,428
-64,475
-4% -$538K ﹤0.01% 1426
2021
Q4 		$12.4M Buy
1,547,903
+209,321
+16% +$1.89M ﹤0.01% 1562
2021
Q3 		$13M Buy
1,338,582
+190,102
+17% +$1.78M ﹤0.01% 1595
2021
Q2 		$11.4M Sell
1,148,480
-260,506
-18% -$2.76M ﹤0.01% 1790
2021
Q1 		$16.3M Sell
1,408,986
-114,337
-8% -$1.31M 0.01% 1472
2020
Q4 		$14.7M Sell
1,523,323
-776,015
-34% -$7.43M 0.01% 1450
2020
Q3 		$20.7M Buy
2,299,338
+139,401
+6% +$1.47M 0.01% 1037
2020
Q2 		$26.6M Buy
2,159,937
+795,681
+58% +$9M 0.01% 865
2020
Q1 		$12.3M Sell
1,364,256
-919,450
-40% -$9.42M 0.01% 1172
2019
Q4 		$22.4M Sell
2,283,706
-479,827
-17% -$4.28M 0.01% 1106
2019
Q3 		$19M Sell
2,763,533
-771,084
-22% -$5.91M 0.01% 1161
2019
Q2 		$32.6M Buy
+3,534,617
New +$42.6M 0.01% 895
2016
Q4 		– Sell
-347,815
Closed -$16M – 1579
2016
Q3 		$16M Sell
347,815
-134,472
-28% -$7.02M 0.09% 253
2016
Q2 		$24.2M Sell
482,287
-36,996
-7% -$1.97M 0.15% 174
2016
Q1 		$27.8M Sell
519,283
-79,958
-13% -$4.69M 0.15% 149
2015
Q4 		$39.3M Buy
599,241
+33,473
+6% +$2.07M 0.2% 99
2015
Q3 		$31.9M Buy
565,768
+124,822
+28% +$8.09M 0.18% 132
2015
Q2 		$26.1M Sell
440,946
-19,368
-4% -$1.19M 0.14% 190
2015
Q1 		$28.7M Sell
460,314
-67,760
-13% -$3.94M 0.16% 175
2014
Q4 		$30.4M Sell
528,074
-11,766
-2% -$656K 0.17% 156
2014
Q3 		$29M Sell
539,840
-1,840
-0.3% -$97.5K 0.18% 140
2014
Q2 		$28.4M Buy
541,680
+264,865
+96% +$13.5M 0.17% 149
2014
Q1 		$14.6M Buy
+276,815
New +$12.8M 0.09% 287

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Nuveen's TEVA Position: Q2 2026 in Review

Nuveen increased its Teva Pharmaceuticals (TEVA) stake by 18% in Q2 2026, buying an estimated $16.3M and bringing the position to 3,230,980 shares worth $109M. The position accounts for 0.03% of the portfolio, ranked #402.

Nuveen first reported a position in TEVA in Q1 2014 and has held it in 40 quarters since. 675 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Nuveen held 3,230,980 shares of Teva Pharmaceuticals worth $109M as of Q2 2026.
  • Nuveen bought 489,957 Teva Pharmaceuticals shares in Q2 2026, an estimated $16.3M.
  • Teva Pharmaceuticals made up 0.03% of Nuveen's portfolio in Q2 2026, its #402 holding.
  • Nuveen first reported a position in Teva Pharmaceuticals in Q1 2014 and has held it in 40 quarters since.
  • 675 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.